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Summary: To evaluate the efficiency of TALEN technol-
ogy for introducing mutations into the mouse genome
we targeted Scn8a, a member of a multigene family
with nine closely related paralogs. Our goal was to gen-
erate a model of early onset epileptic encephalopathy
by introduction of the Scn8a missense mutation
p.Asn1768Asp. We used a pair of TALENs that were
highly active in transfected cells. The targeting tem-
plate for homologous recombination contained a 4 kb
genomic fragment. Microinjection of TALENs with the
targeting construct into the pronucleus of 350 fertilized
mouse eggs generated 67 live-born potential founders,
of which 5 were heterozygous for the pathogenic muta-
tion, a yield of 7% correctly targeted mice. Twenty-four
mice carried one or two Scn8a indels, including 12 fra-
meshift mutations and the novel amino acid deletion
p.Asn1759del. Nine off-site mutations in the paralogs
sodium channel genes Scn5a and Scn4a were identi-
fied. The data demonstrate the feasibility and efficiency
of targeting members of multigene families using TAL-
ENs. The Scn8atm1768DMm mouse model will be useful
for investigation of the pathogenesis and therapy of
early onset seizure disorders. genesis 52:141–148.
VC 2013 The Authors genesis Published by Wiley Periodi-
cals, Inc.
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INTRODUCTION
Mice carrying human pathogenic mutations are valua-
ble tools for analysis of gene function, disease mecha-
nisms, and new therapies. During the past 20 years,
many pathogenic mutations have been introduced into
the mouse genome by homologous recombination in
embryonic stem cells (Menke, 2013). A recently devel-
oped alternative technology employs sequence-specific
endonucleases to target specific sites for mutagenesis.
Zinc finger nucleases, transcription activator-like (TAL)
effector nucleases (TALENs), and RNA guided CRISPR/
Cas nucleases generate site-specific breaks in complex
genomes that are subsequently mis-repaired, either by
nonhomologous end-joining to generate small inser-
tions and deletions or by homologous recombination
with a mutated template to introduce specific changes
into the genome (Meyer et al., 2012; Panda et al., 2013;
Yang et al., 2013). Thus far, these methods have been
most often used for in vitro mutagenesis of cultured
cells, including mouse ES cells. A small number of null
alleles (Davies et al., 2013; Qiu et al., 2013; Sung et al.,
2013) and missense mutations (Panda et al., 2013;
Wefers et al., 2013) have been introduced into the
mouse genome.
We used TALENs to generate a mouse model of the
missense mutation p.Asn1768Asp in the neuronal
sodium channel Nav1.6 encoded by the gene Scn8a.
This de novo mutation was identified in a child with
severe, early onset epileptic encephalopathy by whole
genome sequencing (Veeramah et al., 2012). More than
a dozen de novo mutations of SCN8A have since been
identified by exome sequencing of patients with epilep-
tic encephalopathy or intellectual disability, making
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Scn8a a significant new source of neurological disease
(Allen et al., 2013; Carvill et al., 2013; Rauch et al.,
2012). In addition to de novomutations, a heterozygous
null mutation of SCN8A cosegregated with cognitive
impairment in a human pedigree (Trudeau et al., 2006).
Heterozygous null mutations in the mouse also result in
behavioral abnormalities (McKinney et al., 2008).
SCN8A is a member of a highly conserved multigene
family encoding nine paralogous sodium channels, 7
expressed in neurons and 2 expressed in muscle (Cat-
terall et al., 2008; Meisler et al., 2010; Zakon, 2012).
SCN8A encodes the sodium channel Nav1.6, which is
abundant in the central and peripheral nervous systems
(O’Brien and Meisler, 2013). Nav1.6 is localized at
nodes of Ranvier and at the axon initial segment, where
it regulates neuronal firing (Boiko et al., 2001; Lorincz
and Nusser, 2008; Van Wart et al., 2007).
The previously described mouse mutants of Scn8a
result from partial or complete loss of function muta-
tions (O’Brien and Meisler, 2013). In contrast, the
human epilepsy mutation p.Asn1768Asp exhibits a
dominant gain-of-function due to impaired channel
inactivation (Veeramah et al., 2012). A mouse model of
p.Asn1768Asp will provide novel information regarding
the in vivo effects of Scn8a hyperactivity and the
pathogenesis of epileptic encephalopathy.
RESULTS AND DISCUSSION
Six pairs of TALENs were designed to generate a
double-stranded break near the targeted nucleotide
c.5302A>G in exon 26 of Scn8a, and to maximize mis-
matches with the paralogous sodium channel genes.
Only three of these exhibited nuclease activity in trans-
fected NIH3T3 cells. The TALENs in Figure 1A had the
highest activity and were selected for microinjection.
The targeted nucleotide is located 25 bp downstream
from the predicted endonuclease digestion site in the
spacer between the two TALENs (Fig. 1A, arrow). The
two closest off-site matches identified by the program
TAL Effector Nucleotide Targeter 2.0 Paired Target
Finder (Doyle et al., 2012) are located in the paralogous
genes Scn4a and Scn5a encoding sodium channels
expressed in skeletal and cardiac muscle (Fig. 1C).
The targeting template for homologous recombina-
tion was constructed by cloning a 320 bp fragment
derived from overlapping synthetic oligonucleotides of
190 and 184 bp. The 190 bp oligonucleotide contained
9 single nucleotide differences from the endogenous
Scn8a gene, including the nonsynonymous A>G sub-
stitution encoding the p.Asn1768Asp mutation and a
synonymous change in the spacer region that introdu-
ces a HincII site (Fig. 1B). Seven more synonymous
changes within the TALEN binding sites were intro-
duced in order to minimize redigestion of targeted
alleles. The codon usage for each introduced codon
was 9%. Two flanking genomic fragments were added
to the construct, a 1.5 kb upstream left arm and a 2 kb
downstream right arm. The structure of the targeting
construct, with restriction sites, PCR primers and
hybridization probes, is shown in Figure 2A.
Two rounds of microinjection into fertilized mouse
eggs were carried out using 2.5 ng/ml of circular target-
ing plasmid with two TALEN mRNAs each at 10 ng/ml
(200 eggs) or 20 ng/ml (150 eggs). Sixty-seven potential
founders were obtained, 20 from the first microinjec-
tion and 47 from the second. Mice carrying the intro-
duced mutations were identified by PCR amplification
of a 327 bp fragment containing the targeted site fol-
lowed by digestion with HincII (Fig. 2B). Ten of the 67
mice were positive with this assay. To distinguish
between correct targeting of Scn8a and random inser-
tion of the targeting construct, these 10 mice were ana-
lyzed by Southern blotting of HincII digested genomic
DNA. Hybridization with a probe external to the target-
ing construct detected a 3.5 kb HincII fragment in 5
correctly targeted genomic DNAs (Fig. 2C). The yield of
targeted mice was 5/67 (7%). The targeted allele is des-
ignated Scn8atm1768DMm. Reprobing the Southern blot
with a probe internal to the targeting plasmid identified
8 mice carrying random insertions of the targeting con-
struct, recognized by the 2.2 kb HincII fragment from
within the construct (Fig. 2C). Three of the random
insertions occurred in mice that also carried a correctly
targeted allele. The other 5 mice with random inser-
tions had high copy inserts that interfered with molecu-
lar analysis of the endogenous Scn8a locus, leaving 62
potential founders for analysis of nontargeted mutations
of Scn8a.
Sequencing the targeted site from these 62 potential
founders identified 13 distinct indels in 24 mice (Fig.
3B). Eighteen mice carried a single mutant allele and 6
mice were compound heterozygotes carrying two
indels (Table 1). The Scn8a indels produced frameshift
mutations, with the exception of a 3 bp deletion that
occurred independently in 4 mice and resulted in the
amino acid deletion p.Asn1759del (Fig. 3B). The 6 mice
that were compound heterozygotes for frameshift muta-
tions exhibited the classic Scn8a homozygous null phe-
notype, with hind limb paralysis, muscle wasting and
juvenile lethality. The incorporation into the targeting
vector of 4 synonymous SNPs per TALEN binding site
was apparently effective in preventing redigestion after
homologous recombination, since none of the indels car-
ried the synonymous SNPs. Eight mice appeared to be
mosaic for two different indels plus the wild-type allele,
as indicated by three overlapping sequences from the
amplified PCR product that could not be resolved.
To detect off-site mutations in the most closely
related genomic sequences, we amplified the corre-
sponding fragments of Scn4a and Scn5a and identified
2 indels of Scn4a and 7 indels of Scn5a (Fig. 1C,D). (By
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comparison, there were 37 mutant alleles of Scn8a).
One 9 bp in-frame deletion of Scn5a and one 18 bp in-
frame deletion of Scn4a were observed. The Scn4a and
Scn5a mutations occurred in mice that also carried one
or two mutations of Scn8a (Table 1), suggesting that a
subset of injected eggs expressed a high level of TALEN
activity. No mutations were detected in the more diver-
gent Scn10a gene, with 5 mismatches in one TALEN
site (Fig. 1).
The highly efficient targeting of Scn8a observed in
this study confirms the recent evidence that TALEN
microinjection is a practical method for introducing
FIG. 1. TALEN binding sites in Scn8a and paralogous sodium channel genes. (A) Repeat variable diresidue (RVD) sequence for left and
right TALENs directing the FokI endonuclease to a site within exon 26 of mouse Scn8a. The HD residue (green) binds the C nucleotide; NI
(pink) binds A; NG (blue) binds T; NN (yellow) binds G. The targeted nucleotide for introduction of the epilepsy mutation p.Asn1768Asp is
marked with an arrow. (B) Nine nucleotide substitutions (yellow) were incorporated into the targeting construct to prevent redigestion after
homologous recombination with the targeting construct. One substitution introduced the HincII site used for genotyping (blue arrow). (C)
Sequences of the TALEN targeted site in paralogs from the sodium channel multigene family. Dots represent sequence identity. The most
closely related paralogs sites are in Scn4a and Scn5a, with 1 or 2 bp mismatches per TALEN binding site. The third closest site in the mouse
genome is in Scn10a, with 5 mismatches in one binding site.
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specific nucleotide substitutions into the mouse
genome. The 19% yield of live-born animals (67/350) is
comparable to that obtained during routine generation
of transgenic mice by microinjection. The 7% yield of
mice carrying correctly targeted alleles means that only
a single round of microinjection is required to generate
a mutation of interest. In contrast, targeting of Scn8a by
homologous recombination in ES cells, which do not
express Scn8a, generated only 2/480 targeted clones
(0.4%) (Levin and Meisler, 2004). The presence of
closely related paralogous genes did not produce an
excess of off-site mutagenesis, with 37 independent
mutations in the Scn8a locus and only 9 off-site muta-
tions in the most closely related loci, Scn4a and Scn5a.
We used a targeting template containing 4 kb of
genomic DNA in order to maximize the yield of targeted
alleles. Reported yields of 2% correct targeting with a
144 bp oligonucleotide template for a pigmentation
FIG. 2. Structure of the targeting construct and genotype assays to detect targeted alleles and random insertions. (A) The 6.3 kb targeting
construct was generated from a 320 bp synthetic fragment (red) containing 9 nucleotide substitutions (Fig. 1B) plus flanking genomic frag-
ments of 1.5 and 2.0 kb and the vector sequence of 3 kb (not shown). Arrows represent the PCR primers used to amplify a 327 bp fragment
containing the targeted site for genotyping and sequencing. The indicated external probe was used for hybridization of Southern blots with
HincII digested genomic DNA, generating a 3.5 kb HincII fragment from correctly targeted Scn8a loci. The internal probe was used to detect
random insertions of the targeting construct by hybridization to the internal 2.2 kb HincII fragment generated from the HincII site in the vec-
tor. (B) Detection of mice carrying the HincII site from the targeting vector by PCR amplification of the 327 bp genomic fragment (see A) fol-
lowed by digestion with HincII. M, 100 bp ladder; WT, wild-type; Mu, mutant with the introduced HincII site. Fragment sizes in bp. (C)
Distinction between correctly targeted Scn8a and random insertion of the targeting construct by Southern blot of HincII digested genomic
DNA followed by hybridization with the external probe (left) or the internal probe (right). Three representative genomic DNA samples are
shown, containing a targeted allele, a random insertion, or both. MW markers in kb at right.
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FIG. 3. TALEN generated mutations in Scn8a and off-site mutations in two sodium channel paralogs. The 327 bp fragment shown in Fig-
ure 2A was amplified from the genomic DNA of 62 potential founder mice and sequenced. (A) Sequence chromatogram from a founder
mouse carrying Scn8atm1768DMm. The 9 nucleotide substitutions from the targeting construct in Figure 1B were detected in heterozygous
state (yellow). (B) Genomic sequence of the Scn8a locus from 24 founder mice carrying 13 different indels. (C, D) Genomic sequence from
7 founders carrying 5 different indels in the cardiac sodium channel Scn5a and two indels in the muscle sodium channel Scn4a. The wild-
type sequences are shown in Figure 1C. The number of independent alleles observed is indicated at the right. *: homozygote.
gene (Wefers et al., 2013) and 7% correct targeting of
Fus with a 140 bp oligonucleotide template (Panda
et al., 2013), indicate that construction of a targeting
vector may be unnecessary for some applications.
CRISPR targeting using a targeting construct produced
a yield of 10% correctly targeted offspring, but with an
apparently higher rate of off-site mutation among the
correctly targeted mice (Yang et al., 2013). (We had no
off-target mutations in the 5 correctly targeted mice).
Thus, for targeting a multi-gene family, TALENs may pro-
vide greater specificity.
The p.Asn1768Asp mutation has been transmitted
through the germline from two founder mice to 50% of
heterozygous offspring (12/25 in one line and 13/22 in
the other). The heterozygous p.Asn1768Asp/1 off-
spring do exhibit the key clinical features of the patient
with epileptic encephalopathy, including behavioral
abnormalities, seizures, and SUDEP (sudden unex-
pected death in epilepsy). Unrelated visible phenotypes
have not been observed. This new disease model will
be valuable for analysis of the neuronal consequences
of a hyperexcitable allele of Scn8a, and for characteriz-
ing its response to antiseizure drugs and other treat-
ments. Detection of novel human mutations by exome
sequencing is increasing rapidly. The efficient genera-
tion of accurate mouse models using TALEN and related
technology will greatly facilitate future investigations of
human genetic disorders.
METHODS
Scn8a Specific TALENs
Six pairs of Scn8a-specific TALENs were designed
and tested in transfected NIH 3T3 cells by PNA Bio.
(Thousand Oaks, CA). The TALEN constructs employ
the standard RVD code and linker between TALE and
Fok1 domains (Cermak et al., 2011). Endonuclease
activity was evaluated by PCR amplification of Scn8a
with the primers 8aTAL-F (50 CCATC TTTGGG ATGTC
CAAC 30) and 8aTAL-R (50 GGATG TCCAA GCAGT
GGATT 3 0) as described (http://pnabio.com/products/
TALEN.htm). The nucleotide sequences of the two TAL-
ENs shown in Figure 1A.
Targeting Construct
The template for homologous recombination was
constructed as follows: (1) Synthesis of oligonucleo-
tides of 190 and 184 bp in length with a 34 bp overlap
(Integrated DNA technologies). The forward primer
contained 9 nucleotide differences from the C57BL/6J
genome (Fig. 1B). F oligo (50 CCCTG ACTGC AGCTT
GGACA AGGAG CACCC AGGAA GTGGC TTCAA
AGGGG ACTGC GGGAA CCCCT CCGTG GGCAT
CTTCT TCTTC GTCAG CTACA TCATT ATCTC TTTTC
TCATT GTGGT TAACA TGTAC ATCGC CATTA TTTTG
GAGGA CTTCA GCGTA GCCAC AGAGG AAAGC
GCCGA TCCTC TGAGC 30), the R oligo (50 GGCGA
TGAGC TCGAT GGTGT TGGGC TTGGG TACTC
GGAGC GGATG CTCCA GGGCG TCGGC AAAGT
CGGCC AGCTT ACAGT ACTCG ATGAA CTGGG
TGGCA TCAGG ATCAA ACTTC TCCCA GATCT CATAG
AAAGT CTCGA AGTCG TCCTC GCTCA GAGGA
TCGGC GCTTT CCTCT GTGGC TAC 30). The combined
oligonucleotides acted as primer and template in a PCR
reaction containing 13 Phusion HF buffer, 0.2 mM
dNTPs and 1 unit Phusion Taq DNA Polymerase
(Thermo Scientific) in 50 ml. The reaction was incu-
bated at 98C for 30 s followed by 35 cycles of 98C for
10 s and 72C for 15 s, with a final 10 min extension at
72C. The 340 bp product was gel purified, sequentially
digested with PstI and SacI to generate a 320 bp frag-
ment, and ligated into the 2.5 kb vector pSP72 (Prom-
ega) to generate clone 1. (2) PCR amplification of the
1.5 kb left arm fragment from C57BL/6J genomic DNA
was carried out with the forward primer 50 CACAC
ACTCG AGTCT TCTGG CTTAA AACCA TCAGG 30 and
the reverse primer 50 TCCAA GCTGC AGTCA GGGGG
GCGGT TCAGG ATTG 30. The gel-purified fragment
was digested with PstI and XhoI and ligated into clone
1 to generate clone 2. (3) The 2.0 kb right arm fragment
was amplified from genomic DNA using the forward
primer 50 CAGTT CATCG AGTAC TGTAA GCTGG 30
and the reverse primer 50ACACA CATCG ATCTT ATCTC
AGCCA ACACT GCTGT C 30. The gel purified fragment
was digested with SacI and ClaI and ligated into clone 2
to generate the full length 6.3 kb targeting construct.
Microinjection of TALEN mRNA and Targeting
Construct into Fertilized Eggs
Polyadenylated and 50 capped mRNA was synthesized
from each TALEN using the mMessage mMachine T7
Ultra Kit and purified using the MEGAclear Kit (Ambion
by Life Technologies, Carlsbad, CA). Circular targeting
construct DNA (2.5 ng/ml) and TALEN mRNAs (10 or 20
ng/ml each) in 10 mM Tris-HCl, 0.1 mM EDTA were
Table 1
Genotypes and Allelic Distribution of Sodium Channel Mutations
in 62 Offspring Obtained by Microinjection of TALENs and a 4 kb
Targeting Construct
Scn8a Scn5a Scn4a # mice
1/1 1/1 1/1 33
tar/1 1/1 1/1 3
tar/2 1/1 1/1 2
1/2 1/1 1/1 15
1/2 1/2 1/1 3
2/2 1/1 1/1 2
2/2 1/2 1/1 2
2/2 1/2 1/2 2
62
Tar, targeted mutations in the endogenous Scn8a locus; 2:
null alleles caused by small insertions and deletions;1: wild-type.
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microinjected into the pronucleus of (C57BL/6J 3
SJL)F2 fertilized eggs in the University of Michigan
Transgenic Animal Core, Thom Saunders, Director
(www.med.umich.edu/tamc/).
Genotyping Potential Founders
Tail biopsies were digested with 1 mg/ml proteinase
K in 100 mM NaCl, 100 mM EDTA, 50 mM TrisHCl,
pH 8.0, 1% SDS followed by extraction with phenol
and chloroform and precipitation with ethanol. A 327
bp genomic fragment containing the targeted site of
Scn8a was amplified with the primers Tar-F (50 TGACT
GCAGC TTGGA CAAGG AGC 30) and Tar-R (50 TCGAT
GGTGT TGGGC TTGGG TAC 30). PCR products were
digested with HincII and analyzed on 2% agarose gels
to identify mice carrying the introduced HincII site in
the TALEN spacer. For Southern blots, 10 mg of DNA
was digested with HincII and electrophoresed through
0.8% agarose. Fragments were transferred to Zetaprobe
GT nylon membrane (BioRad Laboratories) and hybri-
dized with 32P-dCTP-labeled probes. The external
probe for detection of correctly targeted Scn8a was
amplified from C57BL/6J genomic DNA with the pri-
mers 30UTR-F (50 CCACT TGGTC TTGTT TCTAC
GACG 30) and 30UTR-R (50 CCTAG CAGGA TCAAA
TAGCT GTTGC 30). After autoradiography, the blot
was stripped and reprobed with the 2.0 kb right arm
DNA fragment (internal probe) to detect random trans-
gene insertions which contain the HincII site from the
vector (Fig. 1A). Molecular weight markers, 100 bp lad-
der and 1 kb ladder, from New England Biolabs.
Sequencing of Targeted Scn8a and Identification
of Indels
The 327 bp genomic fragment containing the targeted
site of Scn8a locus was amplified as described in the pre-
ceding section and sequenced from both strands by
Sanger Sequencing in the University of Michigan
Sequencing Core. The corresponding fragments of
Scn4a and Scn5a were amplified using the primers
Scn4a-F (50 CGACA TTGGA GAACC CAGGC AC 30),
Scn4a-R (50 AAGCT TGATC TTATT GGGCT TGGCA 30),
Scn5a-F (50 AACCT GCCCA ACAGC AATGG CTC 30) and
Scn5a-R (50 AACCT GCCCA ACAGC AATGG CTC 30).
Animals
Mice were housed and cared for in accordance with
NIH guidelines. Experiments were approved by the
University of Michigan Committee on the Use and Care
of Animals. Mutant mice are available to the research
community.
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